1.上海中医药大学附属市中医医院(上海 200071)
陶雨晨,男,博士研究生,主要从事中医药防治血液病的临床与实验研究工作
陆嘉惠,教授,主任医师,博士研究生导师;E-mail:lujiahui73@163.com
扫 描 看 全 文
陶雨晨,陆嘉惠,邓剑青,等.陆嘉惠中西医结合治疗原发免疫性血小板减少症的决策思路[J].上海中医药杂志,2022,56(11):38-42.
TAO Yuchen,LU Jiahui,DENG Jianqing,et al.Decision⁃making strategies of Lu Jiahui in treating primary immune thrombocytopenia with integrated traditional Chinese and western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(11):38-42.
陶雨晨,陆嘉惠,邓剑青,等.陆嘉惠中西医结合治疗原发免疫性血小板减少症的决策思路[J].上海中医药杂志,2022,56(11):38-42. DOI: 10.16305/j.1007-1334.2022.2203045.
TAO Yuchen,LU Jiahui,DENG Jianqing,et al.Decision⁃making strategies of Lu Jiahui in treating primary immune thrombocytopenia with integrated traditional Chinese and western medicine[J].Shanghai Journal of Traditional Chinese Medicine,2022,56(11):38-42. DOI: 10.16305/j.1007-1334.2022.2203045.
对原发免疫性血小板减少症(ITP)治疗现状进行梳理,并根据临床实际,找寻ITP中医药治疗切入点,提出ITP中西医结合治疗的决策思路,认为应在现代医学对ITP规范化治疗基础上,加上中医药精准的辨证论治,扬长避短,优势互补。并附验案2则。
This paper sorts out the current treatment situation of primary immune thrombocytopenia (ITP), and according to the clinical reality, looks for the breakthrough point of ITP treatment in traditional Chinese medicine, and puts forward the decision-making ideas of ITP treatment in the integrative traditional Chinese and western medicine. Based on the standardized treatment of ITP in western medicine, combined with the accurate treatment based on syndrome differentiation of traditional Chinese medicine, the advantages are fostering strengths and avoiding weaknesses, even complementary. And two proven cases are presented.
原发免疫性血小板减少症特发性血小板减少性紫癜中西医结合治疗辨证论治临床经验
primary immune thrombocytopeniaidiopathic thrombocytopenic purpuraintegrated Chinese and western medicine treatmenttreatment based on syndrome differentiationclinical experience
COOPER N, GHANIMA W. Immune thrombocytopenia[J]. N Engl J Med, 2019, 381(10): 945-955.
PROVAN D, ARNOLD D M, BUSSEL J B, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood Adv, 2019, 3(22): 3780-3817.
中华医学会血液学分会血栓与止血学组. 成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)[J]. 中华血液学杂志,2020, 41(8): 617-623.
PROVAN D, SEMPLE J W. Recent advances in the mechanisms and treatment of immune thrombocytopenia[J]. Bio Medicine, 2022, 76: 103820.
YANG R, YAO H, LIN L, et al. Health-related quality of life and burden of fatigue in chinese patients with immune thrombocytopenia: a cross-sectional study[J]. Indian J Hematol Blood Transfus, 2020, 36(1): 104-111.
朱文伟,陈信义,周永明. 成人原发免疫性血小板减少症中医诊治专家共识[J]. 中华中医药杂志,2022, 37(4): 2129-2133.
NEUNERT C, LIM W, CROWTHER M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood, 2011,117(16): 4190-4207.
ZITEK T, WEBER L, PINZON D, et al. Assessment and management of immune thrombocytopenia (ITP) in the emergency department: current perspectives[J]. Open Access Emerg Med, 2022, 14: 25-34.
ZHOU H, FAN J, HE J, et al. Comparative efficacy of 19 drug therapies for patients with idiopathic thrombocytopenic purpura: a multiple-treatments network meta-analysis[J]. Ann Hematol, 2022, 101(5): 953-961.
WONG R, SALEH M N, KHELIF A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study[J]. Blood, 2017, 130(23): 2527-2536.
LAMBERT M P, GERNSHEIMER T B. Clinical updates in adult immune thrombocytopenia[J]. Blood, 2017, 129(21): 2829-2835.
FREDERIKSEN H, MAEGBAEK M L, NORGAARD M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study[J]. Br J Haematol, 2014, 166(2): 260-267.
鲍海军,温成平,谢志军,等. 激素治疗肾病综合征不同阶段中医证型特点的研究[J]. 中医研究,2009, 22(11): 14-15.
陈瑶,李达. 激素依赖性特发性血小板减少性紫癜中医干预的探讨[J]. 中国中西医结合杂志,2011, 31(2): 276-279.
陈瑶,李达. 100例激素依赖性特发性血小板减少性紫癜患者中医证候的多元统计分析[J]. 中国中医基础医学杂志,2012, 18(6): 672-674.
鲍计章,赵心华,周永明,等. 生血灵联合小剂量糖皮质激素治疗激素抵抗型免疫性血小板减少症53例[J]. 西部中医药,2018, 31(2): 5-8.
徐海涛. 生血灵治疗免疫性血小板减少症的疗效观察和对肠道菌群的影响[D]. 上海:上海中医药大学,2019.
GHANIMA W, GERNSHEIMER T, KUTER D J. How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment[J]. Blood, 2021, 137(20): 2736-2744.
KUBASCH A S, KISRO J, HESSLING J, et al. Disease management of patients with immune thrombocytopenia-results of a representative retrospective survey in Germany[J]. Ann Hematol, 2020, 99(9): 2085-2093.
VIANELLI N, AUTERI G, BUCCISANO F, et al. Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives[J]. Ann Hematol, 2022, 101(5): 963-978.
NEWTON J L, REESE J A, WATSON S I, et al. Fatigue in adult patients with primary immune thrombocytopenia[J]. Eur J Haematol, 2011, 86(5): 420-429.
许毅,黄振翘. 黄振翘教授调补泻火法治疗难治性特发性血小板减少性紫癜经验介绍[J]. 新中医,2005, 37(9): 12-13.
SHAW J, KILPATRICK K, EISEN M, et al. The incidence and clinical burden of immune thrombocytopenia in pediatric patients in the United States[J]. Platelets, 2020, 31(3): 307-314.
NEUNERT C, TERRELL D R, ARNOLD D M, et al. American society of hematology 2019 guidelines for immune thrombocytopenia[J]. Blood Adv, 2019, 3(23): 3829-3866.
0
浏览量
257
下载量
0
CSCD
0
CNKI被引量
关联资源
相关文章
相关作者
相关机构